Search Results - "Laramas, M."

Urachal carcinoma: a large retrospective multicentric study from the French Genito-Urinary Tumor Group by Guerin, M, Miran, C, Colomba, E, Cabart, M, Herrmann, T, Pericart, S, Maillet, D, Neuzillet, Y, Deleuze, A, Coquan, E, Laramas, M, Thibault, C, Abbar, B, Mesnard, B, Borchiellini, D, Dumont, C, Boughalem, E, Deville, J L, Cancel, M, Saldana, C, Khalil, A, Baciarello, G, Flechon, A, Walz, J, Gravis, G

“…Urachal cancer (UrC) is a rare, non-urothelial malignancy. Its natural history and management are poorly understood. Although localized to the bladder dome,…”
Get full text

Combined hormone therapy and radiation therapy for locally advanced prostate cancer by Bolla, M, Laramas, M

“…Abstract The combination of radiotherapy and androgen suppression with luteinizing hormone releasing hormone agonist has become a standard of care for locally…”
Get full text

PRM143 Cluster Analysis and Principal Component Analysis to Assess the Variability of Data in Cost Evaluations: Methods and Applications in Oncology by Perrier, L, Buja, A, Mastrangelo, G, Sylvestre Baron, P, Pauwels, P, Ricardo Rossi, C, Gilly, F.N, Ducimetière, F, Favier, B, Farsi, F, Laramas, M, De Marliave, H, Collard, O, Cellier, D, Blay, J.Y, Ray Coquard, I

Get full text

Adjuvant Lymph Node Radiotherapy and Immunotherapy in Stage III Melanoma by Marxgut, L., Verry, C., Desagneaux, A., Charles, J., Laramas, M.

“…With the promising results of immunotherapy (IT) in patients with stage III melanoma, the role of adjuvant radiotherapy (RT) after resection and complete…”
Get full text

Cancer de prostate métastatique résistant à la castration : le point de vue de l’oncologue médical by Laramas, M., Costan, C., Tessier, A., Farneti, D.

“…La majorité des patients atteints d’un cancer de prostate métastatique vont développer une maladie résistante à la castration. Cette situation fréquente…”
Get full text

Paraneoplastic Acute Diffuse Encephalitis Revealing Hodgkin's Disease by Epaulard, O, Courby, S, Pavese, P, Grand, S, Laramas, M, Molina, L, Brion, JP, Colle, P-E, Sotto, JJ

“…Paraneoplastic neurological syndromes are associated with various cancers. Cerebellar and limbic paraneoplastic manifestations are known to be associated with…”
Get full text

465P Larotracking: Real-life study of locally advanced/metastatic solid tumor treated with larotrectinib in French expanded access program by Dufresne, A., Huillard, O., Dalban, C., Geier, M., Wassermann, J., Zanetta, S., Cabourg, M., Catargi, B., El Kouri, C., Hrab, I., Laramas, M., Moreira, A., Saada, E.B., Tournigand, C., Valentin, T., Vauleon, E., Mayet, R., Perol, D., Blay, J-Y.

Get full text

Outcomes of adjuvant lymph node field radiotherapy and immunotherapy for stage III melanoma by Marxgut, Léa, Desagneaux, Andréa, Bellier, Alexandre, Mouret, Stéphane, Charles, Julie, Laramas, Mathieu, Verry, Camille

“…With the promising results of immunotherapy in patients with stage III melanoma, the role of adjuvant radiotherapy after resection and complete lymph-node…”
Get full text

Pronosthyc: Prognostic factors in radioiodine refractory differentiated thyroid cancer with distant metastases, a multicentric study from the French ENDOCAN-TUTHYREF Network by Sagnella, A., Lasolle, H., Godbert, Y., Do Cao, C., Drui, D., Hescot, S., Laramas, M., Sage, C., Wassermann, J., Roudaut, N., Illouz, F., Borson-Chazot, F., Abdelouahab, M.B., Hadoux, J., Borget, I., Buffet, C., Lamartina, L.

“…Radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) patients with distant metastases have a heterogeneous prognosis, spanning from indolent to…”
Get full text

720P Randomised phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen in anti-angiogenic naïve patients with metastatic renal cell carcinoma (mRCC): Interim analysis (IA) of SURF study by Thiery-Vuillemin, A., Gravis, G., Constans Schlurmann, F., Bompas, E., Rolland, F., Gross-Goupil, M., Vano, Y.A., Guillot, A., Barthélémy, P., Joly, C., Laramas, M., Dourthe, L.M., Maurina, T., Gauthier Petithuguenin, H., Taillandy, K., Meurisse, A., Vernerey, D., Albiges, L.

Get full text

P192 CaboCombo: interim analyses from an international real-world study assessing the use of cabozantinib plus nivolumab (CaboNivo) as first-line (1L) treatment for advanced Renal Cell Carcinoma (aRCC) by Barthélémy, P., Gimel, P., Bailly, S., Geoffrois, L., Goujon, M., Laramas, M., Park, S.H., Saldana, C., Dutailly, P., Perrot, V., Qvick, B., Bigot, P.

Get full text

Profil de tolérance des inhibiteurs de checkpoint immunitaire selon le type de cancer by Guérin, C., Laramas, M., Bocquet, A., Bouillet, L., Toffart, A.C.

“…Les inhibiteurs de checkpoint immunitaire (ICI) ont révolutionné les thérapeutiques anti-cancéreuses au cours des dernières années, mais ils ont conduit à…”
Get full text

966PImpact of corticosteroids on nivolumab activity in metastatic clear cell renal cell carcinoma by Lefort, F, Dalban, C, Gross-Goupil, M, Laguerre, B, Barthelemy, P, Sarradin, V, Chanez, B, Negrier, S, Geoffrois, L, Gillon, P, De Vries, M, Ladoire, S, Bolognini, C, Laramas, M, Priou, F, Oudard, S, Chabot, S, Tantot, F, Escudier, B, Albiges, L

“…Abstract Background Nivolumab is a standard of care in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) after failure of prior…”
Get full text

Impact of corticosteroids on nivolumab activity in metastatic clear cell renal cell carcinoma by Lefort, F., Dalban, C., Gross-Goupil, M., Laguerre, B., Barthelemy, P., Sarradin, V., Chanez, B., Negrier, S., Geoffrois, L., Gillon, P., De Vries, M., Ladoire, S., Bolognini, C., Laramas, M., Priou, F., Oudard, S., Chabot, S., Tantot, F., Escudier, B., Albiges, L.

Get full text

966P - Impact of corticosteroids on nivolumab activity in metastatic clear cell renal cell carcinoma by Lefort, F., Dalban, C., Gross-Goupil, M., Laguerre, B., Barthelemy, P., Sarradin, V., Chanez, B., Negrier, S., Geoffrois, L., Gillon, P., De Vries, M., Ladoire, S., Bolognini, C., Laramas, M., Priou, F., Oudard, S., Chabot, S., Tantot, F., Escudier, B., Albiges, L.

“…Nivolumab is a standard of care in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) after failure of prior anti-angiogenic…”
Get full text

Encéphalopathie de Gayet-Wernicke au décours d’une chimiothérapie émétisante by Bourre, J. -C., Laramas, M., Baconnier, M., Ball, P. -M., Pollak, P., Merloz, P., Krainik, A.

“…Résumé Une patiente de 22 ans, prise en charge pour un sarcome d’Ewing claviculaire, a présenté au décours de l’intervention une confusion, une ophtalmoplégie…”
Get full text

Treatment Patterns in Patients with Metastatic Soft Tissue Sarcoma (STS). Results from an Exhaustive Cohort in Rhone-Alpes Region (France), the EMS (Medical Evaluation of Sarcoma) Study by Collard, O., Tehard, B., Ray-Coquard, I., Ladarre, N., Manson, S., Ducimetiere, F., Laramas, M., Blay, J.

Get full text

1511P - Treatment Patterns in Patients with Metastatic Soft Tissue Sarcoma (STS). Results from an Exhaustive Cohort in Rhone-Alpes Region (France), the EMS (Medical Evaluation of Sarcoma) Study by Collard, O., Tehard, B., Ray-Coquard, I., Ladarre, N., Manson, S., Ducimetiere, F., Laramas, M., Blay, J.

“…Soft tissues sarcomas (STS) are rare malignant tumors. Few treatments are approved for metastatic STS and an extent off-label drugs use is expected. Based on a…”
Get full text

Clinical Activity of Sunitinib Rechallenge in Metastatic Renal Cell Carcinoma (Mrcc) – Results of the Resume Study by Oudard, S., Goupil, M. Gross, Geoffrois, L., Guillot, A., Chevreau, C., Deville, J.L., Falkowski, S., Boyle, H., Palmaro, M. Baciuchka, Gimel, P., Laguerre, B., Laramas, M., Pfister, C., Topard, D., Rolland, F., Legouffe, E., Amela, E., Abadie-Lacourtoisie, S., Mahi, N.

Get full text

816PDCLINICAL ACTIVITY OF SUNITINIB RECHALLENGE IN METASTATIC RENAL CELL CARCINOMA (MRCC) – RESULTS OF THE RESUME STUDY by Oudard, S., Goupil, M. Gross, Geoffrois, L., Guillot, A., Chevreau, C., Deville, J.L., Falkowski, S., Boyle, H., Palmaro, M. Baciuchka, Gimel, P., Laguerre, B., Laramas, M., Pfister, C., Topard, D., Rolland, F., Legouffe, E., Amela, E., Abadie-Lacourtoisie, S., Mahi, N.

“…Abstract Aim: Sunitinib is a front-line standard of care in mRCC patients. Several studies have shown that a 2nd line with a TKI after sunitinib progression is…”
Get full text